Component

Human OATP1B1/OATP2B1 transport activity

Species, preparation, dose and limitations are retained on linked claims.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Selected naringenin sulfate or glucuronide conjugates potently inhibited OATP1B1 and/or OATP2B1 in vitro.

    Experimental context and source evidence
    dose
    Naringenin metabolite concentration-response
    duration
    Acute
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Transporter expression assays
    limitations
    The abstract does not assign every conjugate to each transporter or establish interaction at human free concentrations.
    nutrient_topic
    Naringenin chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Naringenin
    organism
    Transporter expression assays
    plain_language
    Selected naringenin sulfate or glucuronide conjugates potently inhibited OATP1B1 and/or OATP2B1 in vitro.
    primary_references
    Interaction of luteolin, naringenin, and their sulfate and glucuronide conjugates with human serum albumin, cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) enzymes and organic anion transporting polypeptide (OATP1B1 and OATP2B1) transporters. (2023). https://pubmed.ncbi.nlm.nih.gov/36481402/ DOI: 10.1016/j.biopha.2022.114078
    route
    In vitro
    tissue
    OATP1B1 and OATP2B1 transport

    Naringenin: mechanism of action and interactions (2026-09-20) · lines 88–97

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Transporter expression assays · source_derived_draft · unverified_draft

    ## naringenin-oatp-inhibition Selected naringenin sulfate or glucuronide conjugates potently inhibited OATP1B1 and/or OATP2B1 in vitro. Model/species: Transporter expression assays Tissue/system: OATP1B1 and OATP2B1 transport Exposure: Naringenin metabolite concentration-response Route: In vitro Duration: Acute Limits: The abstract does not assign every conjugate to each transporter or establish interaction at human free concentrations. Primary reference: Interaction of luteolin, naringenin, and their sulfate and glucuronide conjugates with human serum albumin, cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) enzymes and organic anion transporting polypeptide (OATP1B1 and OATP2B1) transporters. (2023). https://pubmed.ncbi.nlm.nih.gov/36481402/ DOI: 10.1016/j.biopha.2022.114078 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards